The Filing Desk

Dianthus Therapeutics vs Immunome

Dianthus Therapeutics DNTH · Immunome IMNM · Pharmaceuticals

Immunome reported revenue of $7 million in fiscal 2025, 3.5 times Dianthus Therapeutics' $2 million in fiscal 2025. Dianthus Therapeutics' revenue fell 67.3% in its latest year, and Immunome's fell 23.2%. Dianthus Therapeutics had an operating margin of -8739.3%, against -3228.8% at Immunome. Free cash flow was −$129 million at Dianthus Therapeutics and −$201 million at Immunome.

Side by side

Dianthus TherapeuticsImmunome
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$2M$7M
Revenue growth−67.3%−23.2%
Revenue growth a year, last 5 years——
Gross margin——
Operating margin−8,739.3%−3,228.8%
Net margin−7,973.3%−3,060.0%
Free cash flow−$129M−$201M
Free cash flow margin−6,349.4%−2,890.1%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count15.9%49.0%
Last close$91.81$18.77
P/E at the last close——
Insider trades, last 12 monthssold $79.2 millionbought $2.3 million, sold $27.5 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Dianthus TherapeuticsImmunome
Operating margin
Percent of revenue
Dianthus TherapeuticsImmunome
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Dianthus TherapeuticsImmunome

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Dianthus Therapeutics and Immunome pages.